New drugs in the pipeline for the treatment of inflammatory bowel diseases: what is coming?

Ferdinando D'Amico, Laurent Peyrin-Biroulet, Silvio Danese, Gionata Fiorino

Research output: Contribution to journalReview articlepeer-review

Abstract

Over the past twenty years several biological drugs and the first small molecule have been approved for the treatment of patients with inflammatory bowel diseases (IBD). However, a large percentage of patients do not respond to therapies and the demand for new effective drugs is still an unmet need. The better understanding of the pathophysiological mechanisms of disease has allowed to identify new therapeutic targets to block inflammatory pathways. To date, many emerging drugs have been developed and are being tested for both ulcerative colitis and Crohn's disease patients. Here, we summarize the efficacy and safety data of the most promising drugs that could soon enrich the therapeutic armamentarium of IBD patients.

Original languageEnglish
Pages (from-to)141-150
Number of pages10
JournalCurrent Opinion in Pharmacology
Volume55
DOIs
Publication statusPublished - Dec 2020

Fingerprint Dive into the research topics of 'New drugs in the pipeline for the treatment of inflammatory bowel diseases: what is coming?'. Together they form a unique fingerprint.

Cite this